This regulates the stability of SLC1A5 protein, thereby reducing the uptake of glutamine by cells, inhibiting the mechanistic target of rapamycin (mTOR)-signaling pathway and reducing the growth rate of breast cancer cells. The gene discussed is MTOR; the disease is breast carcinoma.